Natural killer cells and single nucleotide polymorphisms of specific ion channels and receptor genes in myalgic encephalomyelitis/chronic fatigue syndrome

Sonya Marshall-Gradisnik1,2
Teilah Huth1,2
Anu Chacko1,2
Samantha Johnston1,2
Pete Smith2
Donald Staines2

1School of Medical Science, 2National Centre for Neuroimmunology and Emerging Diseases, Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD, Australia

Aim: The aim of this paper was to determine natural killer (NK) cytotoxic activity and if single nucleotide polymorphisms (SNPs) and genotypes in transient receptor potential (TRP) ion channels and acetylcholine receptors (AChRs) were present in isolated NK cells from previously identified myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS) patients.

Subjects and methods: A total of 39 ME/CFS patients (51.69±2 years old) and 30 unfatigued controls (47.60±2.39 years old) were included in this study. Patients were defined according to the 1994 Centers for Disease Control and Prevention criteria. Flow cytometry protocols were used to examine NK cytotoxic activity. A total of 678 SNPs from isolated NK cells were examined for 21 mammalian TRP ion channel genes and for nine mammalian AChR genes via the Agena Bioscience iPlex Gold assay. SNP association and genotype was determined using analysis of variance and Plink software.

Results: ME/CFS patients had a significant reduction in NK percentage lysis of target cells (17%±4.68%) compared with the unfatigued control group (31%±6.78%). Of the 678 SNPs examined, eleven SNPs for TRP ion channel genes (TRPC4, TRPC2, TRPM3, and TRPM8) were identified in the ME/CFS group. Five of these SNPs were associated with TRPM3, while the remainder were associated with TRPM8, TRPC2, and TRPC4 (P<0.05). Fourteen SNPs were associated with nicotinic and muscarinic AChR genes: six with CHRNA3, while the remainder were associated with CHRNA2, CHRNA4, CHRNA5, and CHRNA6 (P<0.05). There were sixteen genotypes identified from SNPs in TRP ion channels and AChRs for TRPM3 (n=5), TRPM8 (n=2), TRPC4 (n=3), TRPC2 (n=1), CHRNA (n=1), CHRNA2 (n=2), CHRNA3 (n=1), and CHRNA4 (n=1) (P<0.05).

Conclusion: We identified a number of SNPs and genotypes for TRP ion channels and AChRs from isolated NK cells in patients with ME/CFS, suggesting these SNPs and genotypes may be involved in changes in NK cell function and the development of ME/CFS pathology. These anomalies suggest a role for dysregulation of Ca2+ in AChR and TRP ion channel signaling in the pathomechanism of ME/CFS.

Keywords: chronic fatigue syndrome, myalgic encephalomyelitis, transient receptor potential ion channels, acetylcholine receptors, genotypes

Introduction

Natural killer (NK) cells are granular lymphocytes found in peripheral blood, bone marrow, spleen, and lymph nodes.1-4 In peripheral blood, NK cells comprise 15% of lymphocytes and can be grouped into four subtypes according to the surface expression and

Correspondence: Sonya Marshall-Gradisnik
National Centre for Neuroimmunology and Emerging Diseases, Menzies Health Institute Queensland, Griffith University, Parklands Drive, Southport, Gold Coast, QLD 4222, Australia
Email s.marshall-gradisnik@griffith.edu.au

This article was published in the following Dove Press journal:
The Application of Clinical Genetics
31 March 2016
Number of times this article has been viewed
density of CD56 (neural cell-adhesion molecule) and CD16 (FcγIII receptor, the low-affinity receptor for IgG). These phenotypes include CD56brightCD16dim, CD56dimCD16bright, CD56dimCD16+ bright, and CD56+CD16+. Approximately 90% of NK cells in peripheral blood are CD56+CD16+ bright, and CD56+ bright comprise approximately 10%. NK cell cytotoxic activity requires a number of regulated processes to ensure apoptosis of the target cell. 

Though little is known about Ca²⁺ signaling in NK cells, it has been observed that the granule-dependent pathway of apoptosis is calcium-dependent, whereas the death receptor pathway is not. In apoptosis, lytic protein transport, exocytosis, and fusion have clearly shown calcium dependence. Moreover, studies have demonstrated the relationship between calcium mobilization and the abrogation of degranulation in NK PLCγ2-deficient cells.

Transient receptor potential (TRP) ion channels are expressed on almost all cells, and have a significant effect on physiological functions. Dysregulation in TRPs has been associated with pathological conditions and diseases, such as cancer, skeletal abnormalities, pain syndrome, glomerulonephritis, Omlsted syndrome, mucolipidosis, and polycystic kidney disease. TRP ion channels are activated in the presence of irritants, inflammatory products, and xenobiotic toxins, and have an important role in Ca²⁺ signaling.

Acetylcholine (ACh) binds to two membrane proteins, namely the muscarinic receptor (mAChR) and nicotinic receptor (nAChR), of which there are multiple isoforms. ACh performs nonneuronal functions, termed the nonneuronal cholinergic system, comprising β-pancreatic cells, glial cells, lymphocytes, ocular lens cells, and brain vascular endothelium, which is mediated through Ca²⁺ signaling. AChRs transmit activation signals in a variety of human tissues, including skeletal and smooth muscle, all preganglionic autonomic nerve fibers, postganglionic autonomic parasympathetic nerves, and in many locations throughout the central nervous system.

Myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS) has an unknown etiology, and there is no specific diagnostic test. The illness is largely characterized by significant impairment in physical activity and debilitating fatigue, and can be accompanied by impairment in memory, cognition, and concentration, enhanced experience of muscle and joint pain, headaches, sore throat, and tender lymph nodes. It is further associated with dysregulation of the gastrointestinal, cardiovascular, and immune systems.

Importantly, NK cell dysfunction, in particular reduced NK cell cytotoxic activity, is a common finding in ME/CFS patients. We have previously identified single-nucleotide polymorphisms (SNPs) in TRP ion channel genes and AChR genes, namely TRPM3, TRPA1, TRPC4, CHRM3, CHRNA10, CHRNAS, and CHRNA2 in peripheral blood mononuclear cells from ME/CFS patients. These SNP anomalies in genes for TRP ion channels and AChRs may produce altered receptor proteins, potentially changing TRP ion channel and AChR structures and also functions.

The aim of the present study was to determine NK cytotoxic activity, as well as whether SNPs and their genotypes were present in TRP ion channel and AChR genes in isolated NK cells from ME/CFS patients.

Subjects and methods

Subjects

ME/CFS patients were defined in accordance with the 1994 Centers for Disease Control and Prevention criteria for CFS. A total of 39 ME/CFS patients and 30 unfatigued controls recruited for this study reported no medical history, symptoms of prolonged fatigue, or illness of any kind, and were screened for major disease according to routine pathology tests. All participants provided informed written consent and all samples were deidentified for the purposes of analysis. This study was approved by the Griffith University Human Research Ethics Committee (MSC22/12HREC).

Sample preparation and measurements

A total volume of 80 mL of blood was collected from the antecubital vein of all participants into lithium-heparinized and ethylenediaminetetraacetic acid (EDTA) collection tubes between 9 am and 11 am. Routine blood samples were analyzed from 10 mL of blood within 6 hours of collection and analyzed for red blood cell counts, lymphocytes, granulocytes, and monocytes using an automated cell counter (ACT differential analyzer; Beckman Coulter, Brea, CA, USA) (Table 1).

NK cell isolation

NK cells were isolated from 40 mL of whole blood using Ficoll-Paque (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) and performed using an NK isolation kit (Miltenyi Biotech, Bergisch Gladbach, Germany) according to the manufacturer’s instructions. NK cell purity was measured after staining with CD56 and CD3 antibodies and analyzed using a FACSCalibur flow cytometer (BD Biosciences, San Diego, CA, USA). NK cells were reported as the percentage
of positive CD56+CD3+ cells. Isolated NK cells were either used to measure NK cell cytotoxicity activity or snap-frozen in liquid nitrogen and stored at −80°C until further SNP assessment.

**NK cell cytotoxicity**

NK cytotoxic activity was conducted as previously described. Briefly, following NK lymphocyte isolation using density-gradient centrifugation and labeling with 0.4% PKH-26 (Sigma-Aldrich, St Louis, MO, USA), NK cells were incubated with K562 cells for 4 hours at 37°C in 95% air, 5% CO2, at an effector to target (E:T) ratio of 25 (NK cells):1 (K562). An E:T ratio of 25:1 has been previously shown by us and other researchers to be the most optimal ratio for assessing cytotoxic activity.

NK cell lysis activity was determined after incubating K562 cells for 4 hours, and was calculated to determine induced tumor-cell death or apoptosis. FACScalibur flow cytometry using annexin V–fluorescein isothiocyanate and 7-aminoactinomycin reagents (BD Biosciences) was employed. NK cytotoxic activity was performed within 2–4 hours upon receipt of all blood samples.

**DNA extraction**

A volume of 40 mL was collected into EDTA tubes for SNP analysis. Genomic DNA was extracted from isolated NK cell samples using the Qiagen DNA blood minikit as per manufacturer’s instructions (Qiagen NV, Venlo, the Netherlands). SNP-genotyping studies were performed as previously described.

| Table 1 Participant characteristics for ME/CFS and unfatigued controls |
|--------------------------|------------------|------------------|
| Variable                 | ME/CFS, n=39     | Unfatigued controls, n=30 | P-value |
| Sex (% female)           | 71.79%           | 56.67%            | 0.228   |
| Mean age (years)         | 51.69±2          | 47.6±2.39         | 0.191   |
| Hemoglobin (g/L)         | 136.05±2.07      | 138.8±2.24        | 0.375   |
| Hematocrit (%)           | 0.41±0.01        | 0.41±0.01         | 0.702   |
| Red-cell count (<1012/L) | 4.5±0.07         | 4.58±0.08         | 0.697   |
| Mean corpuscular volume (FL) | 89.97±0.55   | 90.07±0.7         | 0.917   |
| White-cell count (<1012/L) | 5.95±0.26       | 6.38±0.31         | 0.747   |
| Neutrophils (<109/L)     | 3.53±0.19        | 3.96±0.26         | 0.173   |
| Lymphocytes (<109/L)     | 1.91±0.1         | 1.97±0.08         | 0.64    |
| Monocytes (<109/L)       | 0.34±0.02        | 0.32±0.02         | 0.41    |
| Eosinophils (<109/L)     | 0.33±0.18        | 0.37±0.23         | 0.892   |
| Basophils (<109/L)       | 0.20±0.18        | 0.02±0.10         | 0.385   |
| Platelets (<1012/L)      | 262.56±18.41     | 256.79±9.58       | 0.653   |

Note: Data presented as mean ± standard deviation.
Abbreviations: ME, myalgic encephalomyelitis; CFS, chronic fatigue syndrome.

**SNP analysis**

A total of 678 SNPs from isolated NK cells were examined for 21 mammalian TRP ion channel genes (TRPA1, TRPC1, TRPC3, TRPC4, TRPC6, TRPC7, TRPM1, TRPM2, TRPM3, TRPM4, TRPM5, TRPM6, TRPM7, TRPM8, TRPV1, TRPV2, TRPV3, TRPV4, TRPV5, and TRPV6) and for nine mammalian AChR genes (muscarinic M1, M2, M3, M4, M5, nicotinic α2, α3, α5, α7, α10, and ε), and were examined using a MassArray iPLEX Gold assay (Sequenom Inc, San Diego, CA, USA). Quality and quantity of the DNA extracted was determined by a NanoDrop, where approximately 2 μg of genomic DNA was used to perform the SNP analysis. SNP analysis was performed as previously described. Briefly, the MassArray (matrix-assisted laser desorption/ionization time-of-flight mass-spectrometry platform) was employed to discriminate alleles based on single-base extension of an extension primer of known mass that was designed to attach directly next to the SNP site of interest. Custom multiplexed wells were designed in silico using Agena’s Assay Design Suite. The designed multiplexes were then built using custom synthesized oligonucleotides that were pooled together for sample processing. The iPLEX Gold chemistry utilized two multiplexed oligo pools for each genotyping well. These were pooled and balanced prior to running against DNA samples. First, a multiplexed polymerase chain reaction (PCR) pool was utilized to generate short amplicons that included all the genomic markers of interest in that particular well. After PCR and cleanup steps were undertaken, a secondary PCR “extension” step was undertaken, utilizing pools of extension primers that were designed to attach directly next to the SNP sites of interest. A termination mix was added to the extension phase, which allowed these extension primers to be extended by a single base only. As the molecular weight of the extension primer was known, discrimination of the allele was able to be measured using the peak heights of the unextended primer (UEP) and this primer plus the possible single-base extension possibilities for the SNP.

**TRP ion channel and AChR SNP assays**

For each SNP, two PCR primers and one extension primer were created using the Assay Designer (Sequenom) according to the manufacturer’s instructions. A tag was added to the 5’-end of the sequence for each primer. This was done to increase their mass so they were not detected by MassArray when analyzing the extension primers. DNA was amplified via PCR under the following conditions: 94°C for 2 minutes, 94°C for 30 seconds, 56°C for 30 seconds, and 72°C for 1 minute. Amplification products were then treated with shrimp alkaline phosphatase at 37°C for 40 minutes, 85°C for 5 minutes’ reaction, and a final...
incubation at 4°C. Extension primers were optimized to control the signal-to-noise ratio, where UEPs are examined on the SpectroChip and evaluated in Typer 4.0 to enable the division into low-mass UEP, medium-mass UEP, and high-mass UEP. To perform the iPLEX extension reaction, a mixture containing iPLEX Gold reaction was prepared using iPLEX Gold Buffer Plus, iPLEX termination mix, iPLEX enzyme, and primer mix. The iPLEX reaction was cycled at an initial denaturation of 94°C for 30 seconds, annealing at 52°C for 5 minutes, extension at 80°C for 5 minutes (five cycles of annealing and extension were performed, but the whole reaction was performed in 40 cycles), and extension again at 72°C for 3 minutes. Resin beads were used to rinse all iPLEX Gold reaction products. Following the iPLEX Gold reaction, spectrometry was performed using the MassArray mass spectrometer, and the data generated were analyzed using the TyperAnalyzer software.

Statistical analysis
Statistical analysis was performed using SPSS software version 22 (IBM Corporation, Armonk, NY, USA). The experimental data represented in this study are reported as mean ± standard error of the mean, while all the clinical data are reported as mean ± standard deviation. Comparative assessments among participants (ME/CFS and unfatigued controls) were performed with analysis of variance, and the criterion for significance was set at P<0.05.

The Plink version 1.07 (http://pngu.mgh.harvard.edu/purcell/plink) whole-genome-analysis tool set was used to determine associations between the ME/CFS patients and the unfatigued control group. A two-column χ² test was used to examine differences where P<0.05 was determined to be significant, and the resulting variants and their consequences can be found in Table 2 for TRP and AChR, respectively. Further genotype analysis for differences between CFS and the unfatigued group was also completed according to a two-column χ² test with significance set at P<0.05. Analyses were performed at the Australian Genome Research Facility Ltd, Walter and Eliza Hall Institute, Melbourne, Australia.

Table 2 Analysis of frequency, distribution, and significance of SNPs in genes for TRP ion channels and AChRs in ME/CFS patients and unfatigued controls in rank order of significance

<table>
<thead>
<tr>
<th>Gene</th>
<th>CL</th>
<th>SNP</th>
<th>BPs</th>
<th>𝜆₁</th>
<th>FM</th>
<th>FC</th>
<th>𝜆₂</th>
<th>χ²</th>
<th>OR</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>TRPM8</td>
<td>2</td>
<td>rs17865678</td>
<td>2.34a</td>
<td>A</td>
<td>0.4595</td>
<td>0.1667</td>
<td>G</td>
<td>12.88</td>
<td>4.25</td>
<td>0.000332</td>
</tr>
<tr>
<td>TRPM8</td>
<td>2</td>
<td>rs11562304</td>
<td>2.34a</td>
<td>A</td>
<td>0.3553</td>
<td>0.1167</td>
<td>G</td>
<td>10.18</td>
<td>4.172</td>
<td>0.00142</td>
</tr>
<tr>
<td>CHRNA4</td>
<td>15</td>
<td>rs12441088</td>
<td>78,635,922</td>
<td>G</td>
<td>0.1795</td>
<td>0.3793</td>
<td>T</td>
<td>6.824</td>
<td>0.358</td>
<td>0.008993</td>
</tr>
<tr>
<td>TRPC4</td>
<td>13</td>
<td>rs2985167</td>
<td>37,656,405</td>
<td>G</td>
<td>0.2821</td>
<td>0.5</td>
<td>A</td>
<td>6.742</td>
<td>0.3929</td>
<td>0.009418</td>
</tr>
<tr>
<td>TRPM3</td>
<td>9</td>
<td>rs6560200</td>
<td>71,365,306</td>
<td>T</td>
<td>0.3974</td>
<td>0.6207</td>
<td>C</td>
<td>6.633</td>
<td>0.4031</td>
<td>0.01001</td>
</tr>
<tr>
<td>TRPM3</td>
<td>9</td>
<td>rs1106948</td>
<td>71,402,258</td>
<td>T</td>
<td>0.3974</td>
<td>0.6167</td>
<td>T</td>
<td>6.521</td>
<td>0.41</td>
<td>0.0166</td>
</tr>
<tr>
<td>TRPM8</td>
<td>2</td>
<td>rs7658653</td>
<td>2.34a</td>
<td>A</td>
<td>0.2436</td>
<td>0.45</td>
<td>G</td>
<td>6.502</td>
<td>0.3936</td>
<td>0.01078</td>
</tr>
<tr>
<td>CHRNA3</td>
<td>15</td>
<td>rs12914835</td>
<td>78,606,381</td>
<td>T</td>
<td>0.4872</td>
<td>0.2833</td>
<td>C</td>
<td>5.879</td>
<td>2.403</td>
<td>0.01532</td>
</tr>
<tr>
<td>CHRNA2</td>
<td>8</td>
<td>rs891398</td>
<td>74,467,305</td>
<td>C</td>
<td>0.5526</td>
<td>0.3448</td>
<td>T</td>
<td>5.714</td>
<td>2.347</td>
<td>0.01683</td>
</tr>
<tr>
<td>TRPM3</td>
<td>9</td>
<td>rs12350232</td>
<td>71,417,232</td>
<td>G</td>
<td>0.3974</td>
<td>0.6</td>
<td>T</td>
<td>5.571</td>
<td>0.4397</td>
<td>0.01826</td>
</tr>
<tr>
<td>CHRNA2</td>
<td>8</td>
<td>rs2741343</td>
<td>74,467,610</td>
<td>C</td>
<td>0.5526</td>
<td>0.35</td>
<td>T</td>
<td>5.537</td>
<td>2.294</td>
<td>0.01862</td>
</tr>
<tr>
<td>TRPM3</td>
<td>9</td>
<td>rs11142822</td>
<td>71,427,327</td>
<td>T</td>
<td>0.03846</td>
<td>0.15</td>
<td>C</td>
<td>5.314</td>
<td>0.2267</td>
<td>0.02115</td>
</tr>
<tr>
<td>CHRNA3</td>
<td>15</td>
<td>rs2869546</td>
<td>78,615,003</td>
<td>T</td>
<td>0.2763</td>
<td>0.4667</td>
<td>T</td>
<td>5.274</td>
<td>0.4364</td>
<td>0.02168</td>
</tr>
<tr>
<td>CHRNA3</td>
<td>15</td>
<td>rs1891301</td>
<td>71,403,580</td>
<td>T</td>
<td>0.5769</td>
<td>0.3833</td>
<td>C</td>
<td>5.085</td>
<td>2.194</td>
<td>0.02414</td>
</tr>
<tr>
<td>CHRNA3</td>
<td>15</td>
<td>rs9512656</td>
<td>78,586,199</td>
<td>T</td>
<td>0.4359</td>
<td>0.2586</td>
<td>C</td>
<td>4.536</td>
<td>2.215</td>
<td>0.03319</td>
</tr>
<tr>
<td>TRPC2</td>
<td>11</td>
<td>rs7108612</td>
<td>3,628,856</td>
<td>T</td>
<td>0.1923</td>
<td>0.0667</td>
<td>G</td>
<td>4.509</td>
<td>3.333</td>
<td>0.03372</td>
</tr>
<tr>
<td>TRPC2</td>
<td>11</td>
<td>rs6578398</td>
<td>3,616,831</td>
<td>A</td>
<td>0.3462</td>
<td>0.1833</td>
<td>G</td>
<td>4.506</td>
<td>2.358</td>
<td>0.03378</td>
</tr>
<tr>
<td>CHRM1</td>
<td>11</td>
<td>rs6578398</td>
<td>62,920,797</td>
<td>A</td>
<td>0.2436</td>
<td>0.1034</td>
<td>G</td>
<td>4.354</td>
<td>2.791</td>
<td>0.03691</td>
</tr>
<tr>
<td>CHRM3</td>
<td>1</td>
<td>rs4620530</td>
<td>2.4a</td>
<td>T</td>
<td>0.4744</td>
<td>0.3</td>
<td>G</td>
<td>4.301</td>
<td>2.106</td>
<td>0.03809</td>
</tr>
<tr>
<td>CHRM1</td>
<td>11</td>
<td>rs11823728</td>
<td>62,909,330</td>
<td>T</td>
<td>0.05263</td>
<td>0.1607</td>
<td>C</td>
<td>4.242</td>
<td>0.2901</td>
<td>0.03943</td>
</tr>
<tr>
<td>CHRNA3</td>
<td>15</td>
<td>rs424308</td>
<td>78,619,330</td>
<td>G</td>
<td>0.4395</td>
<td>0.2667</td>
<td>C</td>
<td>4.204</td>
<td>2.125</td>
<td>0.04034</td>
</tr>
<tr>
<td>CHRNA3</td>
<td>15</td>
<td>rs3743075</td>
<td>78,617,110</td>
<td>A</td>
<td>0.2821</td>
<td>0.45</td>
<td>T</td>
<td>4.177</td>
<td>0.4802</td>
<td>0.04097</td>
</tr>
<tr>
<td>CHRNA3</td>
<td>15</td>
<td>rs3743074</td>
<td>78,617,138</td>
<td>C</td>
<td>0.2821</td>
<td>0.45</td>
<td>T</td>
<td>4.177</td>
<td>0.4802</td>
<td>0.04097</td>
</tr>
<tr>
<td>CHRNAE</td>
<td>17</td>
<td>rs33970119</td>
<td>4,901,607</td>
<td>A</td>
<td>0.03846</td>
<td>0.1333</td>
<td>G</td>
<td>4.161</td>
<td>0.26</td>
<td>0.04136</td>
</tr>
<tr>
<td>CHRNA5</td>
<td>15</td>
<td>rs7180002</td>
<td>78,581,651</td>
<td>T</td>
<td>0.4342</td>
<td>0.2667</td>
<td>A</td>
<td>4.084</td>
<td>2.11</td>
<td>0.0433</td>
</tr>
</tbody>
</table>

Notes: SNPs of 39 CFS/Me patients and 30 unfatigued controls. Data presented all P<0.05.
Abbreviations: SNPs, single-nucleotide polymorphisms; TRP, transient receptor potential; AChRs, acetylcholine receptors; ME, myalgic encephalomyelitis; CFS, chronic fatigue syndrome; CL, chromosome location; BPs, base pairs; FM, frequency of A₁/A₂ allele in ME/CFS cases; FC, frequency of A₁/A₂ allele in controls; OR, odds ratio.
**Results**

**Participants**
There were 39 CFS patients (age 51.69±2 years), of which 71.79% were females. There were 30 unfatigued controls (age 47.60±2.39 years), of which 56.67% were females. All participants in both groups were of European descent and were residents of Australia at the time of blood collection. There were no significant changes in white blood-cell counts between ME/CFS patients and the unfatigued control group. Table 1 outlines participants’ characteristics.

**NK cell purity**
There was no significant difference between groups for levels of NK purity. Figure 1 outlines the high levels of purity (>93%) of NK cells following isolation and enrichment.

**NK cell cytotoxic activity**
There was a significant difference for NK cytotoxic activity between groups at the E:T ratio of 25:1. ME/CFS patients had a significant reduction in NK percentage lysis of target cells (17%±4.68%) compared with the control group (31%±6.78%) (Figure 2).

**SNP analysis**
Of 678 SNPs identified in TRP ion channel and AChR genes from isolated NK cells, there were eleven SNPs for TRP ion channel genes (TRPC4, TRPC2, TRPM3, and TRPM8) that were significantly associated in the ME/CFS group. Five of these SNPs were associated with TRPM3 (rs6560200, P=0.01; rs1106948, P=0.01; rs12350232, P=0.018; rs11142822, P=0.021; rs1891301, P=0.024) while the remainder were associated with TRPM8 (rs17865678, P=0; rs1156320, P=0.001), TRPC2 (rs7108612, P=0.034; rs6578398, P=0.0334), and TRPC4 (rs2985167, P=0.001; rs655207, P=0.018).

Fourteen SNPs were associated with nicotinic and muscarinic AChR genes, where six were CHRNA3 (rs12914385, P=0.015; rs2869546, P=0.021; rs951266, P=0.033; rs4243084, P=0.040; rs3743075, P=0.041; rs3743074, P=0.041), while the remainder were associated with CHRNA2 (rs891398, P=0.017; rs2741343, P=0.019), CHRN4 (rs12441088, P=0.009), CHRNA5 (rs7180002, P=0.043), and CHRNA4 (rs33970119, P=0.041). Table 2 presents the SNPs for TRP ion channel and AChR genes isolated from NK cells.

**Genotype analysis**
There were 16 genotypes identified from SNPs that were reported significant for TRPM3 (n=5), TRPM8 (n=2), TRPC4 (n=3), TRPC2 (n=1), CHRNA2 (n=1), CHRNA4 (n=2), CHRNA3 (n=1), and CHRNA4 (n=1). Of the significant SNPs identified in Table 2, we further analyzed whether genotypes differed between groups. Table 3 presents the genotypes for SNPs in TRP and AChR genes from isolated NK cells that were reported as statistically significant between groups. The odds ratios for specific genotypes for SNPs in TRP and AChR genes are presented in Table 3.
genes from isolated NK cells ranged between 3.13 and 11.39 for ME/CFS compared with the unfatigued control group.

**Discussion**

Reduced NK cell cytotoxic activity has previously been reported in ME/CFS, and the current investigation supports these findings. The current investigation reports novel findings for a number of SNPs in genes for AChR and TRP variants and genotypes from isolated NK cells from ME/CFS patients. A further novel finding from this investigation is the identification of SNPs in TRPM3 and TRPM8 from isolated NK cells, suggesting TRPM3 and TRPM8 receptors are located on NK cells.

Our investigation reports a significant reduction in NK lysis in ME/CFS patients compared with the unfatigued controls. The role of TRP ion channels in Ca^{2+} signaling and innate and adaptive immune cells is being increasingly documented. TRPs have been reported to express TRP cation channel and TRP melastatin subfamilies, mainly TRPC1, TRPC3, TRPC5, TRPM2, TRPM4, and TRPM7. These channels are nonselective and permeable to calcium. In NK cells, Ca^{2+} plays a key role in lytic granule fusion, as well as ensuring lytic granules mobilize to the immune synapse to release perforin and granzymes to kill target cells. The Rho GTPase Miro provides a link between the mitochondria and the microtubules, where it mediates the Ca^{2+}-dependent arrest of mitochondrial motility. As Miro modifies mitochondrial polarization, it may also alter lytic granule transport to the immune synapse as well as lytic function, due to modulation by cytosolic Ca^{2+} concentration through TRP melastatin and AChR genes. Clearly, mitochondria play a key role in NK cell function. A recent discovery that mitochondria express a range of AChR subtypes, including nicotinic α3, although differentially expressed according to tissue type, suggests that nAChRs may impact mitochondrial function and regulate oxidant stress. Interestingly, we have previously reported a significant decrease in respiratory burst function of neutrophils from ME/CFS patients.

**Table 3** Analysis of genotype, ORs, and significance of SNPs in genes for TRP ion channels and AChRs in ME/CFS patients and unfatigued controls in rank order of significance

<table>
<thead>
<tr>
<th>Gene</th>
<th>CL</th>
<th>SNP</th>
<th>Genotype</th>
<th>ME/CFS, n (%)</th>
<th>Unfatigued controls, n (%)</th>
<th>χ²</th>
<th>OR</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>TRPM8</td>
<td>2</td>
<td>rs11563204</td>
<td>GA</td>
<td>23 (82.1)</td>
<td>5 (17.9)</td>
<td>12.59</td>
<td>7.19</td>
<td>0</td>
</tr>
<tr>
<td>CHRNA2</td>
<td>8</td>
<td>rs891398</td>
<td>GA</td>
<td>11 (91.7)</td>
<td>1 (8.3)</td>
<td>7.3</td>
<td>11.39</td>
<td>0.007</td>
</tr>
<tr>
<td>CHRNA2</td>
<td>8</td>
<td>rs2741343</td>
<td>GA</td>
<td>11 (91.7)</td>
<td>1 (8.3)</td>
<td>7.3</td>
<td>11.39</td>
<td>0.007</td>
</tr>
<tr>
<td>TRPC4</td>
<td>13</td>
<td>rs2985167</td>
<td>GA</td>
<td>20 (76.9)</td>
<td>6 (23.1)</td>
<td>7.07</td>
<td>4.21</td>
<td>0.008</td>
</tr>
<tr>
<td>TRPM3</td>
<td>9</td>
<td>rs6560200</td>
<td>GA</td>
<td>15 (83.3)</td>
<td>3 (16.7)</td>
<td>7.12</td>
<td>5.63</td>
<td>0.008</td>
</tr>
<tr>
<td>TRPC4</td>
<td>13</td>
<td>rs1570612</td>
<td>GA</td>
<td>30 (68.2)</td>
<td>14 (31.8)</td>
<td>6.72</td>
<td>3.81</td>
<td>0.01</td>
</tr>
<tr>
<td>CHRNA2</td>
<td>15</td>
<td>rs12441088</td>
<td>GA</td>
<td>25 (71.4)</td>
<td>10 (28.6)</td>
<td>6.42</td>
<td>3.57</td>
<td>0.011</td>
</tr>
<tr>
<td>CHRNA2</td>
<td>15</td>
<td>rs17865678</td>
<td>GA</td>
<td>22 (73.3)</td>
<td>8 (26.7)</td>
<td>6.1</td>
<td>3.56</td>
<td>0.013</td>
</tr>
<tr>
<td>TRPC4</td>
<td>13</td>
<td>rs655207</td>
<td>GA</td>
<td>12 (85.7)</td>
<td>2 (14.3)</td>
<td>6.09</td>
<td>6.22</td>
<td>0.014</td>
</tr>
<tr>
<td>CHRNA3</td>
<td>15</td>
<td>rs12914385</td>
<td>GA</td>
<td>12 (85.7)</td>
<td>2 (14.3)</td>
<td>6.09</td>
<td>6.22</td>
<td>0.014</td>
</tr>
<tr>
<td>TRPM3</td>
<td>9</td>
<td>rs11142822</td>
<td>GA</td>
<td>36 (63.2)</td>
<td>21 (36.8)</td>
<td>5.87</td>
<td>5.14</td>
<td>0.015</td>
</tr>
<tr>
<td>TRPM3</td>
<td>9</td>
<td>rs1106948</td>
<td>GA</td>
<td>15 (78.9)</td>
<td>4 (21.1)</td>
<td>5.37</td>
<td>4.06</td>
<td>0.021</td>
</tr>
<tr>
<td>TRPC2</td>
<td>11</td>
<td>rs7108612</td>
<td>GA</td>
<td>15 (78.9)</td>
<td>4 (21.1)</td>
<td>5.37</td>
<td>4.06</td>
<td>0.021</td>
</tr>
<tr>
<td>CHRNB4</td>
<td>17</td>
<td>rs33970119</td>
<td>GA</td>
<td>36 (62.1)</td>
<td>22 (37.9)</td>
<td>4.56</td>
<td>4.36</td>
<td>0.033</td>
</tr>
<tr>
<td>TRPM3</td>
<td>9</td>
<td>rs1891301</td>
<td>GA</td>
<td>14 (77.8)</td>
<td>4 (22.2)</td>
<td>4.48</td>
<td>3.64</td>
<td>0.034</td>
</tr>
<tr>
<td>TRPM3</td>
<td>9</td>
<td>rs1235023</td>
<td>GA</td>
<td>15 (75)</td>
<td>5 (25)</td>
<td>3.91</td>
<td>3.13</td>
<td>0.048</td>
</tr>
</tbody>
</table>

Notes: Genotypes from 39 ME/CFS patients and 30 unfatigued controls. Data presented all P<0.05; df=1 for basic allelic test.

Abbreviations: ORs, odds ratios; SNPs, single-nucleotide polymorphisms; TRP, transient receptor potential; AChRs, acetylcholine receptors; ME, myalgic encephalomyelitis; CFS, chronic fatigue syndrome; CL, chromosome location.
SNPs in genes for two of the CHRM3 receptors, two CHRM1 receptors, six CHRNA3 receptors, three CHRNA2 receptors, and one CHRNA5 receptor, as well as one CHRNA4 receptor and one CHRNAE receptor.

Our current research reports significant SNP associations of genotypes for AChRs in isolated NK cells from ME/CFS patients. Lymphocytes expressed both muscarinic and nicotinic AChRs, where T- and B-cells and monocytes expressed all five subtypes of mAChRs (M1–M5), while nAChRs were found for α2–α7, α9, α10, β2, and β10 subunits.33–56 Lymphocytes constitute a cholinergic system that is independent of cholinergic nerves, resulting in the regulation of immune function.53,54 AChR agonists have been shown to enhance lymphocyte cytotoxicity and increase their intracellular cyclic guanosine monophosphate and inositol-1,4,5-triphosphate,55,57 suggesting the lymphocytic cholinergic system is involved in the regulation of immune function via AChRs coupled to PLC via changes in Ca2+.58–63 Previous research has highlighted the importance of variants in affecting gene transcripts by causing alternative splicing, resulting in anomalies in messenger RNA and translation products.64 We have also identified SNPs and genotype in CHRNAE in ME/CFS patients. Interestingly, this SNP is located in the 3'-untranslated region, which is a binding site for regulatory proteins as well as microRNAs (miRNAs).65 Binding to specific sites within the 3'-untranslated region, miRNAs can decrease gene expression of various messenger RNAs by either inhibiting translation or directly causing degradation of the transcript. Our previous research has found significant differences in NK cytotoxic activity, as well as in miRNAs from isolated NK cells from ME/CFS patients.32

Previous investigations have suggested that alternate splicing in the coding and also in the noncoding sequences may have significant unexpected outcomes on the splicing mechanism of the gene transcripts.64,66 Splicing genetic variants located in the exons, introns, and the assembly of the spliceosome all contribute to the splicing mechanism for the correct coding of a protein sequence. Moreover, silencers and enhancers located either in the exons or introns are integral in recognition of the correct exon sequence.67 Importantly, introns are able to generate active spliceosomes, giving rise to alternative splicing events.68,69 Gene 80036 (TRPM3) is associated with calcium entry and calcium-store depletion via different isoforms that have been identified through alternative splicing.70 A region that is indispensable for channel function is an 18-amino acid-residue region whose absence renders the channels functionally unable to mediate calcium entry, and is found devoid in a TRPM3 variant.71 Coexpression of these TRPM3 ICF variants with functional TRPM3 ion channels additionally shows impaired calcium mobilization.71 As TRPM3 ICF variants show ubiquitous expression in many tissues and cell types and constitute 15% of all TRPM3 isoforms, expression on NK cells may provide a potential explanation for reduced cytotoxic activity in ME/CFS patients. Particular splice variants, such as TRPM3α1, may potentially be favored, culminating in a diminished NK cell cytotoxic response and heat detection, including dysregulation of thermoregulatory responses, nociception, and transmission of pain, such as central and peripheral pain perception. Moreover, TRPM8 has also been identified to be activated by cold and noxious stimuli,72–74 suggesting that the genotype changes reported in this investigation align with the clinical presentation of thermoregulatory responses, nociception, and transmission of central and peripheral pain perception seen in ME/CFS patients.75

Our results suggest that SNP variants and genotypes reported in NK cells may not be exclusive to this immune-cell type. AChRs and TRP ion channel receptors are located ubiquitously on multiple cell types and control other functions in body systems. Ca2+ signaling in the context of TRP ion channels and AChR function is vital for the function of the central nervous system, and there is wide variety in the nicotinic receptors expressed in animal and human immune cells.66 Of note, nAChRs are reported to be involved in arousal, sleep, and fatigue, as well as those functions that are responsible for processing of pain, memory, and cognition, all of which are clinical symptoms reported in ME/CFS patients.76–78

Conclusion
In this study, we identified, for the first time, SNPs in genes for TRPM3 and TRPM8 ion channels on isolated NK cells. We also identified numerous SNPs of nAChRs along with other TRP channels on isolated NK cells, which may explain the important role of the nonneuronal ACh system in NK cell function. Anomalies in genotypes for TRP ion channels and AChRs suggest that altered calcium would be an important functional consequence not only for NK cells but also depending upon tissue type, susceptibility, or predisposition to ME/CFS.

Author contributions
All authors contributed toward data analysis, drafting and revising the paper and agree to be accountable for all aspects of the work.
Acknowledgments

The authors would like to thank Dr Lavinia Gordon, Australian Genome Research Facility, Melbourne, Australia, for completing the bioinformatics SNP analysis. This study was supported by funding from the Alison Hunter Memorial Foundation, Stafford Fox Medical Research Foundation, Mason Foundation, and Queensland Co-Investment Program.

Disclosure

The authors report no conflicts of interest in this work.

References


The Application of Clinical Genetics 2016:9

submit your manuscript | www.dovepress.com
Dovepress
For personal use only.
Published by Dove Press

Acknowledgments

The authors would like to thank Dr Lavinia Gordon, Australian Genome Research Facility, Melbourne, Australia, for completing the bioinformatics SNP analysis. This study was supported by funding from the Alison Hunter Memorial Foundation, Stafford Fox Medical Research Foundation, Mason Foundation, and Queensland Co-Investment Program.

Disclosure

The authors report no conflicts of interest in this work.

References


